Physician profile
Merit E Cudkowicz
NPI 1306827241
$82,486.32
in general payments reported to CMS, 2019-2025
18 companies · $2,861 in 2025
The $2,861 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $13K · 2021: $4,719 · 2022: $19K · 2023: $12K · 2024: $5,731 · 2025: $2,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $9,840 · Food and Beverage: $59.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,569.00 |
| Consulting Fee | $9,840.25 |
| Food and Beverage | $59.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $22,207.15 | 2019-2023 | |
| Genzyme Corporation | $18,171.28 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $15,845.59 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $5,030.25 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $4,302.00 | 2024 | |
| Tanabe Pharma Corporation | $2,475.00 | 2021 | |
| Orion Corporation | $2,166.67 | 2019 | |
| Eli Lilly and Company | $2,025.00 | 2019-2021 | |
| Tanabe Pharma America, INC. | $1,667.74 | 2019-2022 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $1,634.50 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,500.00 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,434.14 | 2020-2025 | |
| Biomarin Pharmaceutical INC. | $1,116.00 | 2025 | |
| Shionogi INC | $915.00 | 2025 | |
| F. Hoffmann-La Roche Ag | $840.00 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amylyx Pharmaceuticals, INC. | $787.50 | 2024 | Relyvrio |
| Corcept Therapeutics | $368.50 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merit Cudkowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.